The Psoriasis Treatment Pipeline An Overview and Update

被引：8

作者：

Hawkes, Jason E. ^{[1
]}

Al-Saedy, Miriam ^{[2
]}

Bouche, Nicole ^{[2
]}

Al-Saedy, Salsabeal ^{[2
]}

Drew, Delaney T. ^{[3
]}

Song, Eingun James ^{[4
]}

机构：

[1] Pacific Skin Inst, Dept Dermatol Integrat Skin Sci & Res, 1495 River Pk Dr, Sacramento, CA 95815 USA

[2] Elson S Floyd Coll Med, 412 East Spokane Falls Blvd, Spokane, WA 99202 USA

[3] Univ Hosp Reg Hosp, 13207 Ravenna Rd, Chardon, OH 44024 USA

[4] Frontier Dermatol, Dept Dermatol, 15906 Mill Creek Blvd 105, Mill Creek, WA 98012 USA

来源：

DERMATOLOGIC CLINICS | 2024年 / 42卷 / 03期

关键词：

Psoriasis; IL-17A; IL-17F; IL-23; GPP; TYK2; PDE4; AhR; ARYL-HYDROCARBON RECEPTOR; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; INFLAMMATION; BIMEKIZUMAB; MULTICENTER; TAPINAROF; EFFICACY; ANTIBODY; NANOBODY;

D O I：

10.1016/j.det.2024.02.006

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：365 / 375

页数：11

共 50 条

[1] Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin [J].

Akiyama, Masashi ;

Takeichi, Takuya ;

McGrath, John A. ;

Sugiura, Kazumitsu .

JOURNAL OF DERMATOLOGICAL SCIENCE, 2018, 90 (02) :105-111

[2] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [J].

Armstrong, April W. ;

Gooderham, Melinda ;

Warren, Richard B. ;

Papp, Kim A. ;

Strober, Bruce ;

Thaci, Diamant ;

Morita, Akimichi ;

Szepietowski, Jacek C. ;

Imafuku, Shinichi ;

Colston, Elizabeth ;

Throup, John ;

Kundu, Sudeep ;

Schoenfeld, Steve ;

Linaberry, Misti ;

Banerjee, Subhashis ;

Blauvelt, Andrew .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) :29-39

[3] Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review [J].

Armstrong, April W. ;

Read, Charlotte .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19) :1945-1960

[4] Clinical and Molecular Genetics of the Phosphodiesterases (PDEs) [J].

Azevedo, Monalisa F. ;

Faucz, Fabio R. ;

Bimpaki, Eirini ;

Horvath, Anelia ;

Levy, Isaac ;

de Alexandre, Rodrigo B. ;

Ahmad, Faiyaz ;

Manganiello, Vincent ;

Stratakis, Constantine A. .

ENDOCRINE REVIEWS, 2014, 35 (02) :195-233

[5] Trial of Spesolimab for Generalized Pustular Psoriasis [J].

Bachelez, H. ;

Choon, S-E ;

Marrakchi, S. ;

Burden, A. D. ;

Tsai, T-F ;

Morita, A. ;

Navarini, A. A. ;

Zheng, M. ;

Xu, J. ;

Turki, H. ;

Anadkat, M. J. ;

Rajeswari, S. ;

Hua, H. ;

Vulcu, S. D. ;

Hall, D. ;

Tetzlaff, K. ;

Thoma, C. ;

Lebwohl, M. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2431-2440

[6]

Bissonnette R, 2023, WORLD C DERM WCD

[7] Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent [J].

Bissonnette, Robert ;

Gold, Linda Stein ;

Rubenstein, David S. ;

Tallman, Anna M. ;

Armstrong, April .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (04) :1059-1067

[8] Spesolimab: First Approval [J].

Blair, Hannah A. .

DRUGS, 2022, 82 (17) :1681-1686

[9] Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies [J].

Brembilla, Nicolo Costantino ;

Boehncke, Wolf-Henning .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[10]

Christophers E, 2019, J EUR ACAD DERMATOL, V33, P260, DOI [10.1111/jdv.15436, 10.1111/jdv.15339]

← 1 2 3 4 5 →